Squarepoint
RGC icon

Squarepoint’s Regencell Bioscience RGC Stock Holding History

Squarepoint’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Sell
22,036
-4,577
-17% -$110K ﹤0.01% 4149
2026
Q1 		$677K Buy
26,613
+602
+2% +$17K ﹤0.01% 3097
2025
Q4 		$546K Sell
26,011
-25,238
-49% -$410K ﹤0.01% 3136
2025
Q3 		$792K Sell
51,249
-48,594
-49% -$697K ﹤0.01% 2872
2025
Q2 		$1.7M Buy
+99,843
New +$1.22M ﹤0.01% 2216

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return

Squarepoint's RGC Position: Q2 2026 in Review

Squarepoint reduced its Regencell Bioscience (RGC) stake by 17% in Q2 2026, selling an estimated $110K and leaving 22,036 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #4149.

Squarepoint first reported a position in RGC in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.7M in Q2 2025. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Squarepoint held 22,036 shares of Regencell Bioscience worth $134K as of Q2 2026.
  • Squarepoint sold 4,577 Regencell Bioscience shares in Q2 2026, an estimated $110K.
  • Regencell Bioscience made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4149 holding.
  • Squarepoint first reported a position in Regencell Bioscience in Q2 2025 and has held it in 5 quarters since.
  • Squarepoint's Regencell Bioscience position peaked at $1.7M in Q2 2025.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.